- Academic Editor
Background: Single-nucleotide polymorphisms (SNPs) in the proprotein
convertase subtilisin/kexin type 9 (PCSK9) gene are known to be
associated with susceptibility to several cerebrovascular diseases, including
ischemic stroke (IS). The aims of this study was to evaluate associations between
PCSK9 gene polymorphisms and the risk of IS. Based on previous reports
linking PCSK9 SNPs to plasma lipid levels and to atherosclerosis, and to
inconsistencies in the reported associations between the SNPs, plasma lipid
levels and IS risk, we choose the PCSK9 rs505151, rs529787, and
rs17111503 to performe the association analysis. Methods: Using multiple
databases, all relevant case-control and cohort studies that matched our search
criteria were collected. Quality assessment of included studies was performed
using the Newcastle-Ottawa Scale. Demographic and genotype data were extracted
from each study, and meta-analysis was performed using Stata/MP 17.0. Odds ratios
(ORs) with 95% confidence intervals (CIs) were calculated using fixed and random
effects models. Results: A critical evaluation was conducted on ten
case-control studies, involving a total of 2426 cases and 2424 controls. Pooled
results from the allelic models indicated the PCSK9 rs505151 G allele
(OR: 1.41, 95% CI: 1.06–1.87, p = 0.019, I
Ischemic stroke (IS) is a primary cause of fatality, and a significant contributor of disease burden globally [1]. According to statistics from 2019, stroke continues to rank as the second most common cause of death and the third leading cause of disability on a global scale [2]. The etiology of IS can be attributed to a combination of environmental, genetic and vascular risk factors, therefore making IS a complex and multifaceted condition [3]. Risk factors that are often highlighted include obesity, smoking, hyperlipidemia, hypercholesterolemia, hypertension, diabetes, and atherosclerosis [2, 4, 5]. Previous investigations have demonstrated the critical involvement of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene in the progression of atherosclerosis and hyperlipidemia, ultimately culminating in IS [6].
The ninth member of the preprotein convertase family, Bacillus subtilis protease/kexin type 9 (PCSK9), also known as neural apoptosis-regulated convertase 1, has emerged as a significant player in lipid metabolism [7]. Approximately 70% of Low-Density Lipoprotein Cholesterol (LDL-C) clearance is mediated by the low-density lipoprotein receptor (LDLR), and PCSK9 promotes the degradation of hepatic LDLR, thus hindering LDLR recycling to the hepatocyte surface, and contributing to the increased LDL-C levels [8]. One investigation showed that gain-of-function (GOF) mutations in the PCSK9 gene resulted in a 23% decrease in the levels of LDLR expression at the cell surface. In contrast, loss-of-function (LOF) mutations in PCSK9 led to a 16% increase in LDLR levels [9]. As a result, the occurrence of hypercholesterolemia and subsequent IS events may be caused by the action of the PCSK9 gene, in downregulating LDLR expression and thereby inhibiting LDL-C uptake [6, 10].
The PCSK9 gene spans 22 kb on chromosome 1p32.3, is composed of 12
exons, and encodes 692 amino acids [11, 12]. This gene exhibits a high levels of
polymorphism, giving rise to numerous variants [12, 13, 14]. Specifically, a common
GOF mutation called PCSK9 rs505151 (A
Numerous studies have been conducted to investigate the influence of PCSK9 gene polymorphisms on lipid levels and their association with the risk of cardiovascular disease [17]. In the present study, we conducted a comprehensive meta-analysis to provide possible relationships between the rs505151, ra529787, and rs17111503 variants and susceptibility to IS.
This systematic review was carried out following the guidelines of the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement
(PRISMA checklist) (Supplementary-PRISMA_2020_checklist). To retrieve
studies that examined the association between PCSK9 gene polymorphisms
and IS, a thorough literature search was performed on PubMed, Web of Science,
ScienceDirect, and the Chinese literature database CNKI in August 2023. The
retrieval terms used was [“PCSK9” or “proprotein convertase
subtilisin/kexin type 9” or “NARC1” or “neural apoptosis-regulated
convertase 1”] AND [“gene polymorphism” or “SNP” or “single nucleotide
polymorphism”] AND [“stroke” or ”ischemic stroke”]. The inclusion criteria were:
(1) cohort studies and/or case-control studies were considered; (2) data on
PCSK9 gene polymorphisms were available; (3) the presence of sufficient
data to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (4) the
studies included the PCSK9 rs505151, rs529787, and/or rs17111503 allelic data.
The exclusion criteria were: (1) studies that did not provide the required
information; (2) meta-analyses, case reports, reviews, and in vitro
studies; (3) duplicated studies conducted on the same population. The study
quality assessment was performed using the Newcastle-Ottawa Scale (high-quality:
Data extraction from eligible studies was performed independently by two authors (JW and SL) and reviewed by a third author (YR). In case of disagreement, the authors repeated the process until a consensus was reached. Data from each eligible study included general information (first author, publication year, ethnicity of the patients, study type, sample size, age, and sex), SNPs, genotyping method, Hardy-Weinberg equilibrium (HWE), dominant allele count (DAC), minor allele count (MAC), minor allele frequency (MAF).
Associations between the PCSK9 rs505151, rs529787, and rs17111503
polymorphisms and the risk of IS were evaluated using ORs and 95% CIs. Allelic model were primarily used to assess genetic
associations [17]. The heterogeneity of eligible studies was assessed using the
Cochran’s Q test and I
This meta-analysis included 10 studies with a total of 22 comparisons. All were case-control studies. The study quality ranged from moderate (n = 4) to good (n = 6), as shown in Supplementary Table 1. These studies consisted of eight published articles [16, 20, 21, 22, 23, 26, 27, 28] and two theses [29, 30]. The study selection process is shown in Fig. 1. With regard to the PCSK9 rs505151 polymorphism, six studies were identified from the initial search, comprising a total of 3250 subjects (1596 cases and 1654 controls). Of these subjects, 746 (23%) were Asian and 2504 (77%) were Caucasian. Regarding the PCSK9 rs529787 polymorphism, five studies were identified from the initial search, involving 2875 subjects (1527 cases and 1348 controls). Among these subjects, 2162 (62%) were Asian and 713 (38%) were Caucasian. Regarding the PCSK9 rs17111503 polymorphism, four eligible articles were identified that studied the association with IS. These comprised a total of 2349 subjects (1231 cases and 1118 controls), of which 1441 (61%) were Asian and 908 (39%) were Caucasian. Table 1 (Ref. [16, 20, 21, 22, 23, 26, 27, 28, 29, 30]) provides detailed characteristics of all the selected studies and the allele distribution for each individual study.
Flow chart of the research selection process. IS, ischemic stroke; PCSK9, proprotein convertase subtilisin/kexin type 9.
Studies | Year | Ethnicity | Sample size | Age (years) | Sex (M/F) (n) | SNP | Minor allele | Genotyping method | Case (n) | Control (n) | MAF (%) | HWE (p) | |||||
Case | Control | Case | Control | Case | Control | DAC | MAC | DAC | MAC | ||||||||
Abboud, S. et al. [26] | 2007 | Caucasians | 237 | 326 | 53.5 | 73.0 | 158/79 | 215/111 | rs505151 | G | TaqMan | 454 | 20 | 638 | 14 | 3.02 | 0.69* |
Han, D. F. et al. [21] |
2014 | Asians | 250 | 199 | 63.6 |
62.4 |
144/106 | 102/97 | rs505151 | G | SNaPshot | 468 | 32 | 378 | 20 | 5.79 | 0.46* |
Han, D. F. et al. [21] |
2014 | Caucasians | 158 | 149 | 59.4 |
61.2 |
98/60 | 81/68 | rs505151 | G | SnaPshot | 303 | 13 | 279 | 19 | 5.21 | 0.59* |
Slimani, A et al. [16] | 2014 | Caucasians | 114 | 232 | 66 (54.5–76.5) | 49 (45.0–50.0) | 65/49 | 172/60 | rs505151 | G | PCR-RFLP | 200 | 28 | 430 | 34 | 8.96 | 0.81* |
Han, D. F. [29] |
2014 | Asians | 321 | 269 | 63.6 |
62.4 |
187/134 | 141/128 | rs505151 | G | SNaPshot | 596 | 46 | 511 | 27 | 9.24 | 1.00 |
Han, D. F. [29] |
2014 | Caucasians | 205 | 201 | 59.4 |
61.2 |
126/79 | 109/92 | rs505151 | G | SNaPshot | 391 | 19 | 377 | 25 | 5.42 | 0.52 |
Chen, L. L. et al. [27] | 2019 | Asians | 216 | 192 | 55.1 |
54.0 |
101/105 | 90/102 | rs505151 | G | PCR-RFLP | 204 | 228 | 226 | 158 | 47.30 | 0.30* |
Xiang, L [30] | 2020 | Asians | 95 | 86 | 64.3 |
63.7 |
59/36 | 49/37 | rs505151 | G | PCR-RFLP | 163 | 27 | 163 | 9 | 19.89 | 0.61* |
Han, D. F. et al. [21] |
2014 | Asians | 250 | 199 | 63.6 |
62.4 |
98/60 | 81/68 | rs17111503 | A | SNaPshot | 301 | 199 | 268 | 130 | 36.64 | 0.80* |
Han, D. F. et al. [21] |
2014 | Caucasians | 158 | 149 | 59.4 |
61.2 |
65/49 | 172/60 | rs17111503 | A | SNaPshot | 156 | 160 | 152 | 146 | 33.48 | 0.69* |
Han, D. F. [29] |
2014 | Asians | 321 | 269 | 63.6 |
62.4 |
187/134 | 141/128 | rs17111503 | A | SNaPshot | 385 | 257 | 381 | 171 | 36.27 | 0.66 |
Han, D. F. [29] |
2014 | Caucasians | 205 | 201 | 59.4 |
61.2 |
126/79 | 109/92 | rs17111503 | A | SNaPshot | 202 | 208 | 205 | 145 | 43.47 | 0.66 |
Han, D. F. et al. [23] |
2017 | Asians | 147 | 135 | 62.5 |
61.6 |
81/66 | 72/63 | rs17111503 | A | SNaPshot | 177 | 117 | 192 | 78 | 16.84 | 0.91 |
Han, D. F. et al. [23] |
2017 | Caucasians | 90 | 105 | 59.4 |
61.1 |
50/40 | 55/50 | rs17111503 | A | SNaPshot | 92 | 88 | 110 | 100 | 48.21 | 0.94 |
Wei, J. G. et al. [22] | 2022 | Asians | 60 | 60 | 63.6 |
62.3 |
38/22 | 35/25 | rs17111503 | A | PCR-RFLP | 74 | 46 | 95 | 25 | 29.58 | 0.84 |
Han, D. F. et al. [21] |
2014 | Asians | 250 | 199 | 63.6 |
62.4 |
144/106 | 102/97 | rs529787 | G | SNaPshot | 499 | 1 | 390 | 8 | 1.00 | 0.77* |
Han, D. F. et al. [21] |
2014 | Caucasians | 158 | 149 | 59.4 |
61.2 |
98/60 | 81/68 | rs529787 | G | SNaPshot | 291 | 25 | 269 | 29 | 8.79 | 0.70* |
Han, D. F. [29] |
2014 | Asians | 321 | 269 | 63.6 |
62.4 |
187/134 | 141/128 | rs529787 | G | SNaPshot | 641 | 1 | 530 | 8 | 0.76 | 1.00 |
Han, D. F. [29] |
2014 | Caucasians | 205 | 201 | 59.4 |
61.2 |
126/79 | 109/92 | rs529787 | G | SNaPshot | 376 | 34 | 364 | 38 | 8.87 | 0.59 |
Zhang, Y. et al. [20] | 2016 | Asians | 414 | 350 | 61.8 |
61.8 |
246/168 | 185/165 | rs529787 | G | PCR-RFLP | 804 | 24 | 665 | 35 | 3.73 | 0.32* |
Zou, J. et al. [28] | 2021 | Asians | 119 | 120 | 61.3 |
61.8 |
NA | NA | rs529787 | G | SNaPshot | 237 | 1 | 231 | 9 | 2.09 | 0.19* |
Wei, J. G. et al. [22] | 2022 | Asians | 60 | 60 | 63.6 |
62.3 |
38/22 | 35/25 | rs529787 | G | PCR-RFLP | 114 | 6 | 117 | 3 | 3.75 | 0.61 |
As shown in Fig. 2, the allelic model of the G allele (adenine deoxyribonucleotide, A vs G, guanine deoxyribonucleotide) in PCSK9
rs505151 was associated with significantly increased risk of IS (OR = 1.41, 95%
CI: 1.06–1.87, p = 0.019, I
Forest plot for the association between rs505151 and IS risk. CI, confidence interval. DL, DerSimonian-Laird.
Forest plot for the association between rs529787 and IS risk.
Forest plot for the association between rs17111503 and IS risk. MH, Mantel Haenszel.
SNPs | Variant allele | Subgroup | Studies | Sample size | Efforts model | ORs | 95% CI | p | I |
p |
Begg’s (p-value) | Egger’s (p-value) |
rs505151 | G | Caucasians | 4 | 2504 | Random | 1.15 | (0.65, 2.03) | 0.636 | 69.2 | 0.021 | 0.308 | 0.565 |
rs505151 | G | Asians | 4 | 746 | Random | 1.60 | (1.28, 2.00) | 4.0 | 0.373 | 1.000 | 0.480 | |
rs505151 | G | Overall | 8 | 3250 | Random | 1.41 | (1.06, 1.87) | 0.019 | 53.9 | 0.034 | 0.902 | 0.869 |
rs529787 | G | Caucasians | 2 | 713 | Random | 0.84 | (0.58, 1.21) | 0.337 | 0.0 | 0.825 | - | - |
rs529787 | G | Asians | 5 | 2162 | Random | 0.34 | (0.12, 1.02) | 0.054 | 62.7 | 0.030 | 0.086 | 0.194 |
rs529787 | G | Overall | 7 | 2875 | Random | 0.59 | (0.35, 1.00) | 0.051 | 55.8 | 0.035 | 0.072 | 0.024 |
rs17111503 | A | Caucasians | 3 | 1441 | Fixed | 1.19 | (0.98, 1.43) | 0.072 | 43.8 | 0.169 | 0.296 | 0.108 |
rs17111503 | A | Asians | 4 | 908 | Fixed | 1.52 | (1.31, 1.78) | 1.4 | 0.385 | 0.308 | 0.117 | |
rs17111503 | A | Overall | 7 | 2349 | Fixed | 1.38 | (1.22, 1.55) | 43.5 | 0.101 | 1.000 | 0.610 |
-: insufficient observations. Abbreviation: OR, odds ratio; CI, confidence interval.
Table 2 presents the details for heterogeneity and publication bias in the
allelic model. The results of this meta-analysis reveal significant heterogeneity
in the associations between the PCSK9 rs505151 (p = 0.034,
I
Funnel plot of publication bias. (A) rs505151 polymorphism (A vs G) and IS risk. (B) rs529787 polymorphism (C vs G) and IS risk. (C) rs17111503 polymorphism (G vs A) and IS risk. A, Adenine deoxyribonucleotide; G, guanine deoxyribonucleotide; C, cytosine deoxyribonucleotide.
This comprehensive meta-analysis to investigated for associations between the PCSK9 rs505151, rs529787, and rs17111503 polymorphisms and the risk of IS. A total of ten studies (8 articles and 2 theses) were included in the analysis, comprising 2426 stroke cases and 2424 healthy controls. Previous meta-analyses have already shown the PCSK9 rs505151 variant is linked to elevated plasma levels of total cholesterol (TC), triglycerides (TG), LDL-C, and to increased cardiovascular risk [17, 31, 32, 33, 34]. The present study contributes more comprehensive evidence by showing that the rs505151 variant G allele is associated with increased risk of IS. This finding is consistent with a previous study [32], and is also the first meta-analysis to investigate the relationship between the PCSK9 rs17111503 variant A allele and risk of IS. Thus, our study provides valuable information regarding PCSK9 gene polymorphisms and their potential for predicting the risk of IS. This information could serve as a basis for future research and also have implications for clinical work and disease prevention strategies. PCSK9 could also serve as a potential target for the diagnosis and treatment of IS.
Elevated levels of serum LDL-C are linked to the risk of cerebrovascular disease, and particularly IS. PCSK9 plays a crucial role in lipid metabolism [7], as well as regulating the synthesis and secretion of apolipoprotein B [35]. The primary function of PCSK9 is to strongly increase the degradation of LDLR, efectively decreasing its expression in the liver and inhibiting the uptake of LDL-C by hepatocytes [36, 37]. PCSK9 act as both a serine protease and molecular chaperone to reduce hepatic and extrahepatic LDLR levels via the endosomal/lysosomal pathway [38]. While PCSK9 is predominantly expressed in hepatic tissues, it is also present in extrahepatic tissues such as the intestines, kidneys, and blood vessels. Circulating PCSK9 secreted by the kidneys and blood vessels functions to downregulate LDLR levels in diverse cell types, including hepatocytes and macrophages, thereby reducing the uptake of LDL-C by these cells [39]. In the intestine, PCSK9 mainly upregulates cholesterol levels by reducing the secretion of serum LDL-C rather than its uptake [40]. Therefore, PCSK9 affects lipid and lipoprotein levels not only by decreasing hepatic lipoprotein clearance, but also by promoting hepatic lipogenesis [41].
PCSK9 exhibits a high degree of polymorphism. Multiple PCSK9
variants are associated with cholesterol regulation, leading to significant
differences in blood cholesterol levels among the general population and
surpassing the effects of LDLR and Apolipoprotein B (APOB) polymorphisms [42].
PCSK9 variants are categorized into two groups: GOF mutations, linked to
hypercholesterolemia, and LOF mutations, resulting in hypocholesterolemia [17].
Of note, one study reported no associations between the PCSK9 LOF
variants Y142X (rs67608943), R46L (rs11591147), and C679X (rs28362286) and the
risk of stroke [43], although LOF mutations may lower the risk of various
critical extra-coronary atherosclerotic events [44]. The PCSK9 rs505151
variant is classified as a common GOF mutation. A previous study on this variant
confirmed its correlation with cardiovascular disease [17]. Notably, this present
study further elucidated the link between the rs505151 polymorphism and the risk
of IS. Subgroup meta-analysis in the present study showed this association occurs
in Asians, but not in Caucasians. However, there is only a limited amount of
research on genetic variations in the PCSK9 promoter region. This
analysis found some evidence to suggest the A allele of the PCSK9
rs17111503 variant located in the PCSK9 promoter can increase the
susceptibility to IS. Our findings indicate the PCSK9 rs17111503 G
Pharmacogenetic examination have shown that PCSK9 variants are linked to the effectiveness of statin therapy [45, 46, 47]. PCSK9 inhibitors are a novel class of lipid-lowering medications that impede the degradation of LDLR by binding to PCSK9 protein. Numerous studies have shown that PCSK9 inhibitors can reduce LDL-C levels by up to 60%, thereby reduing the likelihood of cerebrovascular events [48]. Consequently, PCSK9 inhibitors could reducing potentially prevent the occurrence of stroke [49]. A recent investigation revealed that combining a PCSK9 inhibitor (evolocumab) with a statin could reduce the incidence of IS among patients with atherosclerosis, including those who had alread experienced an IS [50]. Various methods have been proposed for reducing PCSK9 levels, including the use of siRNAs and antisense oligonucleotides to decrease the PCSK9 gene expression, monoclonal antibodies to impede formation of the PCSK9-LDLR complex, and high-affinity mimetic peptides or synthetic proteins to inhibit the interaction between PCSK9 and LDLR [51]. Furthermore, combination of the PCSK9 rs505151and rs1711503 variants into risk prediction models may improve the accuracy of IS risk prediction and thus help in primary prevention.
There are several limitations to this meta-analysis. Firstly, the data for the rs505151 polymorphism showed some heterogeneity, which could potentially reduce the credibility of the results. Second, the studies included in this analysis did not provide information on IS subtypes, thereby preventing subgroup analysis based on these subtypes. Third, our analysis was based only on the allelic model, because only allelic data were available in some studies and the use of different models can increase type I error [17]. Fourth, this study lacks eligible cohort prospective studies to study possible gene-environment interactions. Fifthly, African American ethnicity was not included. Despite these limitations, the present meta-analysis has contributed valuable insights into the association between several PCSK9 SNPs and the risk of IS.
In summary, the present meta-analysis found that the G allele of PCSK9 rs505151 and the A allele of PCSK9 rs17111503 may increase the risk of IS, particularly in Asian subjects. Based on the above findings, these SNPs could serve as potential targets for the diagnosis and treatment of IS. Although the individual impact of each SNP on disease occurrence might not be readily apparent, the integration of genetic polymorphism information into prediction models of IS risk may prove beneficial during routine clinical practice.
PCSK9, Proprotein convertase subtilisin/kexin type 9; IS, ischemic stroke; TC, total cholesterol; TG, triglycerides; OR, odds ratios; CI, confidence intervals; LDLR, low-density lipoprotein receptor; GOF, gain-of-function; LOF, loss-of-function; SNP, single nucleotide polymorphism; DAC, dominant allele count; MAC, minor allele count; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.
All data generated or analyzed during this study are included in the article material, further inquiries can be directed to the corresponding author.
Conceptualization: JW , WL; Data curation: JW, SL, YR; Formal analysis: JW, SL, GW, WL; Funding acquisition: JW, YR; Writing — original draft: JW, SL; Writing — review & editing: WL. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
Not applicable.
We would like to thanks to all the peer reviewers for their opinions and suggestions.
This research was funded by the Shanxi Provincial Key Research and Development Project, grant number 201903D321127 and 201903D321048.
The authors declare no conflict of interest.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.